PT  - JOURNAL ARTICLE
AU  - Huo, Xiaochuan
AU  - Ma, Gaoting
AU  - Zhang, Xuelei
AU  - Pan, Yuesong
AU  - Tong, Xu
AU  - Sun, Dapeng
AU  - Liu, Liping
AU  - Wang, Yilong
AU  - Liebeskind, David S
AU  - Wang, Yongjun
AU  - Pereira, Vitor Mendes
AU  - Ren, Zeguang
AU  - Miao, Zhongrong
TI  - Endovascular therapy in acute anterior circulation large vessel occlusive patients with a large infarct core (ANGEL-ASPECT): protocol of a multicentre randomised trial
AID  - 10.1136/svn-2022-001865
DP  - 2023 Apr 01
TA  - Stroke and Vascular Neurology
PG  - 169--174
VI  - 8
IP  - 2
4099  - http://svn.bmj.com/content/8/2/169.short
4100  - http://svn.bmj.com/content/8/2/169.full
SO  - Stroke Vasc Neurol2023 Apr 01; 8
AB  - Background The benefit of stroke thrombectomy for large infarct core still lacks robust randomised controlled studies.Aim To demonstrate the design of a clinical trial on endovascular therapy for acute anterior circulation large vessel occlusion (LVO) patients with large infarct core volume.Design ANGEL-ASPECT is a multicentre, prospective, randomised, open-label, blinded End-point trial to evaluate whether best medical management (BMM) combined with endovascular therapy improves neurological functional outcomes as compared with BMM alone in acute LVO patients with Alberta Stroke Program Early CT Score (ASPECTS) of 3–5 on non-contrast CT or infarct core volume range of 70–100 mL (defined as rCBF <30% on CT perfusion or ADC <620 on MRI) up to 24 hours from symptom onset or last seen well.Study outcomes The primary efficacy outcome is 90 (±7) days modified Rankin Scale. Symptomatic intracranial haemorrhage within 48 hours from randomisation is the primary safety outcome.Discussion The ANGEL-ASPECT trial will screen patients with large infarct core (ASPECTS 3–5 or 70–100 mL) through image evaluation criteria within 24 hours and explore the efficacy and safety of endovascular therapy compared with BMM.All data relevant to the study are included in the article or uploaded as online supplemental information.